Interaction between Rivaroxaban and Coagulation factor X human
Moderate
Antagonism
| ID | DDInter1609 and DDInter422 |
| Interaction | Based on their mechanisms of action, the pharmacologic activity of coagulation factor X is likely to be counteracted by direct and indirect factor Xa inhibitors. In vivo, factor X is converted from its inactive form to the active form, factor Xa, by the cleavage of a 52-residue peptide from the heavy chain. |
| Management | Concomitant use of coagulation factor X with direct and indirect factor Xa inhibitors should be avoided. |
| References | |
| Alternative for Rivaroxaban |
B01A
More
|
| Alternative for Coagulation factor X human |
B02B
Anti-inhibitor coagulant complex
Romiplostim
Avatrombopag
Antihemophilic factor, human recombinant
Epinephrine (ophthalmic)
Epinephrine (topical)
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.